(MedPage Today) — Adding the dual checkpoint inhibitor regimen of ipilimumab (Yervoy) and nivolumab (Opdivo) to percutaneous hepatic perfusion significantly reduced the risk of disease progression or death in metastatic uveal melanoma, a single…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
